Table 108Characteristics of the included studies [IC=Intermittent catheterisation. SCI=Spinal Cord Injury]

StudyPatient groupReason for prophylaxisBladder management strategyProphylactic antibioticComparatorFollow upOutcomes
Clarke 2005204Spina bifida; childrenCongenital conditionICContinuation of un-named prophylactic antibioticDiscontinuation of un- named prophylactic antibiotic4 monthsSymptomatic UTI
Zegers 2011206Spina bifida; childrenCongenital conditionICContinuation of un-named prophylactic antibioticDiscontinuati on of un- named prophylactic antibiotic18 monthsSymptomatic UTI
Johnson 1994207Meningocele; childrenCongenital conditionICNitrofurantoin 25–50mg/day depending on body massPlacebo6 monthsSymptomatic UTI
Schlager 1998203Undefined “neurogenic bladder”; childrenCongenital conditionICNitrofurantoin 25–50mg/day depending on body massPlacebo [Cross-over]11 monthsSymptomatic UTI
Adverse events
Anderson 1980208SCI; adultsNew SCIICNitrofurantoin 100mg/daySterile IC onlyUnclearSymptomatic UTI
Gribble 1993209SCI; adultNew SCIICTrimethoprim- sulphamethoxazole 240mg/day (1:5 Ratio)Placebo4 monthsSymptomatic UTI
Adverse events
Lindan 1984210SCI; adultsNew SCIExternal catheter with reflex voiding, IC and Foley catheterisation.Nitrofurantoin 100mg/dayNo treatment (no placebo)3 monthsSymptomatic UTI
Adverse events
Maynard 1984211SCI; adultsNew SCIICTrimethoprim- sulphamethoxazole 480mg/dayNo treatment (no placebo)1.5 monthsSymptomatic UTI
Adverse events
Mohler 1987212SCI; adultsNew SCIICTrimethoprim- sulphamethoxazole 960mg/dayPlacebo2 monthsSymptomatic UTI
Sandock 1995205SCI; adultsNew SCIIC, reflex voiding, indwelling cathetersContinuation of Trimethoprim- sulphamethoxazole 480mg/dayDiscontinuati on of prophylaxis7 monthsSymptomatic UTI
Adverse events
Darouiche 1994213SCI; adultsPrior to urodynamic testingUnclearCiprofloxacin 1g/dayPlacebo18 monthsSymptomatic UTI
Adverse events
Biering-Sorenson 1994201SCI; adultsRecurrent UTIs in mostly long-standing SCI patients.Mixed – abdominal pressure, suprapubic tapping and/or IC.Ciprofloxacin 100mg/dayPlacebo [Cross-over]12 monthsSymptomatic UTI
Adverse events
Duffy 1982202Undefined – “Neurogenic bladder”; adultsNeurogenic bladder clinic patientsICNitrofurantoin 200mg/dayPlacebo [Cross-over]6 monthsAdverse events

From: 13, Treatment to prevent urinary tract infection

Cover of Urinary Incontinence in Neurological Disease
Urinary Incontinence in Neurological Disease: Management of Lower Urinary Tract Dysfunction in Neurological Disease.
NICE Clinical Guidelines, No. 148.
National Clinical Guideline Centre (UK).
Copyright © 2012, National Clinical Guideline Centre.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.